GDF15 and colorectal carcinoma: A recent phase II study (NIPICOL trial) in Microsatellite Instability–High or Deficient Mismatch Repair metastatic colorectal cancer (CRC) patients treated with nivolumab plus ipilimumab demonstrated that high baseline GDF-15 levels were associated with inferior progression-free and overall survival.